ArticleFrontiers in endocrinology2026
Prevalence and predictors of malignancy in Bethesda III and IV thyroid nodules undergoing surgery.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Indeterminate thyroid cytology remains a major diagnostic challenge. Thyroid nodules classified as Bethesda category (BC) III and IV carry an intermediate risk of malignancy, and their management often involves a choice between active surveillance and diagnostic surgery. This study aimed to assess the prevalence of benign, low-risk, and malignant lesions in surgically treated patients with these nodules, and to identify factors associated with malignancy. Methods: We retrospectively analyzed 618 patients with BC III or IV thyroid nodules, selected from 2,239 patients who underwent thyroid surgery between October 2022 and December 2025 at a Tertiary Referral Endocrine Surgery Centre in Krakow. Histopathology followed the 2022 WHO Classification of Thyroid Tumors. Results: The distribution of tumor types differed significantly in both BCs III (n=365) and IV (n=253) nodules (both p<0.001), with benign lesions predominating (62.5% in BC III and 55.7% in BC IV), followed by malignant (30.4% and 32.8%) and low-risk lesions (7.1% and 11.5%), respectively. Younger age was associated with a higher risk of malignancy in both BC III (p=0.03) and BC IV (p=0.02). Sex was associated with lesion distribution in BC III (p = 0.016) but not BC IV (p = 0.06), and was not an independent predictor of malignancy. Tumor size ≥1 cm was associated with malignancy in BC IV (p=0.005), but not in BC III (p=0.35). Although age alone showed limited discriminative ability, multivariable analysis identified age <50 years as the only independent predictor of malignancy (adjusted OR 1.74; 95% CI 1.23-2.47; p=0.002) and lymph node metastasis (adjusted OR 4.56; 95% CI 1.19-17.53; p=0.03), while sex, chronic lymphocytic thyroiditis (CLT), and BC were not significant. Conclusions: In this surgical cohort of BC III and IV thyroid nodules, approximately one-third of lesions were malignant. Younger age was independently associated with malignancy, but its value as an isolated predictor was limited, and the overall discriminative performance of the multivariable model was modest. These findings may support individualized preoperative risk stratification; however, given the retrospective design and the selection of patients for surgery, they do not justify firm conclusions regarding the optimal extent of surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.